1076199-77-3

Basic information

• Product Name: rac 5-Carboxy Tolterodine
• Synonyms: 3-[3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-hydroxy-benzoic Acid;rac 5-Carboxy Tolterodine;5-Carboxy Tolterodine ForMate
• CAS NO: 1076199-77-3
• Molecular Formula: C₂₂H₂₉NO₃
• Molecular Weight: 355.47056
• Product Categories: Various Metabolites and Impurities;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Metabolites & Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1076199-77-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: rac 5-Carboxy Tolterodine(CAS DataBase Reference)
• NIST Chemistry Reference: rac 5-Carboxy Tolterodine(1076199-77-3)
• EPA Substance Registry System: rac 5-Carboxy Tolterodine(1076199-77-3)

Safety Data

• Hazardous Substances Data: 1076199-77-3(Hazardous Substances Data)

Usage

Description

rac 5-Carboxy Tolterodine is a chemical compound that is a metabolite of Tolterodine (T535800) and a degradation product of Fesoterodine (F321300) formed under stress conditions in tablet dosage forms. It is a derivative of Tolterodine, which is a muscarinic antagonist used in the treatment of overactive bladder.

Uses

Used in Pharmaceutical Industry:
rac 5-Carboxy Tolterodine is used as an intermediate in the synthesis of Tolterodine and Fesoterodine for the treatment of overactive bladder. It plays a crucial role in the development of medications that help manage urinary incontinence and other related symptoms.
Used in Research and Development:
rac 5-Carboxy Tolterodine is used as a research compound for studying the properties, mechanisms, and potential applications of Tolterodine and its derivatives. This helps in understanding the compound's behavior and its interaction with other substances, which can lead to the development of new drugs or therapies.
Used in Quality Control and Analysis:
rac 5-Carboxy Tolterodine is used as a reference material in the quality control and analysis of pharmaceutical products containing Tolterodine or Fesoterodine. It helps ensure the purity, potency, and consistency of these medications, contributing to their overall safety and efficacy.

Upstream product

• 87462-12-2 N,N-diisopropyl-3-phenyl-2-propen-1-amine 
• 99-96-7 4-hydroxy-benzoic acid 
• 108-18-9 diisopropylamine 
• 2687-12-9 cinnamyl chloride 
• 214601-12-4 (R)-N,N-diisopropyl-3-phenyl-3-(5-formyl-2-hydroxyphenyl)propyl-1-amine 
• 156755-35-0 methyl 4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]benzoate 
• 214601-16-8 (R)-(-)-3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzoic acid methyl ester 
• 106-41-2 4-bromo-phenol 
• 621-82-9 Cinnamic acid 
• 286930-05-0 (+)-N,N-Diisopropyl-3-(2-benzyloxy-5-carbomethoxyphenyl)-3-phenylpropylamine 
• 837376-33-7 4-(benzyloxy)-3-(3-(diisopropylamino)-1-phenylpropyl)benzaldehyde 
• 214601-54-4 (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanal 
• 156755-23-6 6-bromo-4-phenyl-3,4-dihydro-2H-chromen-2-one 
• 156755-24-7 methyl 3-[2-(benzyloxy)-5-bromophenyl]-3-phenylpropanoate 

Downstream Products

• 1262778-55-1 2-(3-N,N-diisopropylamine-1-phenylpropyl)-4-carboxyphenol isobutyrate 
• 250214-44-9 2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxyl-methyl)phenyl isobutyrate 
• 1390644-42-4 3-(3-(diisopropylamino)-1-phenylpropyl)-4-(methacryloyloxy)benzoic acid 
• 1390644-41-3 (R)-3-(3-(diisopropylamino)-1-phenylpropyl)-4-(methacryloyloxy)benzoic acid 
• 1449220-63-6 L-(-)-menthyl 3-(3-N,N'-diisopropylamino-1(S)-phenyl-propyl)-4-hydroxy-benzoate hydrochloride 
• 1449220-65-8 (S)-3-(3-N,N'-diisopropylamino-1-phenyl-propyl)-4-hydroxy-benzoic acid 
• 286930-02-7 fesoterodine 
• 207679-81-0 (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)-phenol 
• 286930-03-8 fesoterodine fumarate 
• 1449220-60-3 D-(+)-menthyl 3-(3-N,N'-diisopropylamino-1(R)-phenyl-propyl)-4-hydroxy-benzoate hydrochloride 
• 1449220-62-5 racemic 3-(3-N,N'-diisopropylamino-1-phenyl-propyl)-4-hydroxy-benzoyl chloride hydrochloride 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST

The present invention relates to novel and improved processes for the preparation of (r)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenylisobutyrate represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.

PROCESS FOR OBTAINING 3,3-DIPHENYLPROPYLAMINES

The invention relates to a process for obtaining 3,3- diphenylpropylamines of general formula (I), particularly Fesoterodine, as well as their enantiomers, solvates and salts, comprising a chemoselective reduction of the acid group against the ester group